The Outsourcing Facilities Association on Monday (March 10) filed an appeal in the Fifth Circuit after its case to reverse the FDA’s decision to remove tirzepatide from its shortage list last year was denied by a district court in Texas earlier this month. Following the lower court’s decision, FDA has clarified that state-licensed pharmacies or physicians under 503A of the Food, Drug & Cosmetic Act are no longer allowed to compound versions of the GLP-1, while outsourcing facilities under section...